Article

Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer

2021-04-21

Abstract excerpt

<h4>ABSTRACT</h4> High-risk localized prostate cancer (HRLPC) is associated with a substantial risk of recurrence and prostate cancer-specific mortality 1 . Recent clinical trials have shown that intensifying anti-androgen therapies administered prior to prostatectomy can induce pathologic complete responses (pCR) or minimal residual disease (MRD) (<5 mm), together termed exceptional response, although the molec...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a8c2287a-7394-5048-b5f9-c35919245ef7
DOI: 10.1101/2021.04.20.440657

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancerDOI 10.1101/2021.04.20.440657Read

Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancerSemantic proximity Read

Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapySemantic proximity Read

Unravelling the molecular mechanisms of prostate cancer evolution from genotype to phenotype.Semantic proximity Read

Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease ProgressionSemantic proximity Read

Establishing a Prognostic Model in Prostate Adenocarcinoma through Comprehensive scRNA-Seq and Bulk RNA-Seq Analysis and ValidationSemantic proximity Read

Patterns of Structural Variation Define Prostate Cancer Across Disease StatesSemantic proximity Read

Genomic hallmarks of localized, non-indolent prostate cancer.Semantic proximity Read

Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate CancerSemantic proximity Read

Determinant of aggressive phenotype in metastatic hormone sensitive prostate cancer depends on an intrinsic, highly aggressive cell cluster: Integrated single- cell and whole transcriptomic analysesSemantic proximity Read

Integrated analysis of single-cell and bulk transcriptomes uncovers clinically relevant molecular subtypes in human prostate cancerSemantic proximity Read

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.Semantic proximity Read

Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE TrialSemantic proximity Read